Clinical Trial

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Study acronym: ADhope 2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how similar is the current maintenance dosing regimen of lebrikizumab 250 mg every 4 weeks (Q4W) to the new proposed; lebrikizumab 500 mg every 12 weeks (Q12W), in terms of efficacy, safety, PK, ADA and blood biomarkers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-24; most recent amendment 2026-04-20.
Status change: Recruiting → Active, Not Recruiting 2026-04-20
Trial Details
NCT Number NCT06526182
Lead Sponsor Almirall, S.A.
Conditions Dermatitis, Atopic, Eczema
Enrollment 520 participants
Start Date 2024-07-03
Primary Completion 2027-04-25 (estimated)
Study Completion 2027-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-21